Welcome to our dedicated page for Enliven Therapeutics news (Ticker: ELVN), a resource for investors and traders seeking the latest updates and insights on Enliven Therapeutics stock.
Enliven Therapeutics, Inc. (Nasdaq: ELVN) is a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation small molecule treatments for cancer. Located in Boulder, Colorado, the company is driven by a precision oncology approach, aiming to address unmet needs in cancer treatment and improve both survival and overall well-being for patients.
Enliven Therapeutics operates with the support of top-tier life science venture funds and is continuously expanding its research and development team. The company is on the lookout for experienced and passionate drug developers to join their mission.
One of the company’s primary product candidates, ELVN-001, is a highly selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion. This gene fusion is the oncogenic driver in patients with chronic myeloid leukemia (CML). ELVN-001 is designed to address challenges such as resistance and disease escape through brain metastases.
The company also has another promising candidate, ELVN-002, a central nervous system (CNS) penetrant and irreversible HER2 inhibitor. ELVN-002 demonstrates activity against both wild-type HER2 and various HER2 mutations, targeting issues of tolerability and combinability in cancer therapy.
Recent Achievements:
- Hosting a webcast on April 11, 2024, to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia landscape.
- Collaborations with leading CML investigators and hematology care experts to enhance the development and application of ELVN-001.
- Continuous financial growth and strong investor support, as evidenced by their recent financial results for the fourth quarter and full year of 2023.
Enliven Therapeutics continues to push the boundaries of cancer treatment with a commitment to improving patient outcomes through innovative research and development.
For more information, visit the investor relations section of Enliven Therapeutics’ website.
Enliven Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Jefferies London Healthcare Conference on November 19, 2024, at 9:30 a.m. GMT. The company's management will engage in a fireside chat, which will be webcast live. Interested parties can access the webcast via the investor relations section of Enliven's website. The webcast will remain available for 90 days post-event.
Enliven Therapeutics (Nasdaq: ELVN) has announced details for the presentation of updated ELVN-001 Phase 1a data at the ESH-iCMLf 26th Annual John Goldman Conference on CML. The event will take place from September 27-29 in Prague, Czech Republic. ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia (CML) patients.
The oral presentation, titled "Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML," will be delivered by Dr. Fabian Lang from Goethe University Hospital on September 28, 2024, at 3:35 p.m. CEST. The presentation will be part of Scientific Session 5: New drugs and combinations. Enliven will make the presentation available on their website after the conference.
Enliven Therapeutics (Nasdaq: ELVN) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Dosing of first patients in Phase 1b arm for ELVN-001 in CML and Phase 1a trial for ELVN-002 in HER2+ MBC and CRC.
2. Strong financial position with $312.4 million in cash, providing runway into late 2026.
3. R&D expenses increased to $18.8 million in Q2 2024 from $15.2 million in Q2 2023.
4. Net loss widened to $20.0 million in Q2 2024 from $16.7 million in Q2 2023.
5. Upcoming presentation of updated ELVN-001 Phase 1a data at ESH-iCMLf Conference in September 2024.
Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage precision oncology company, has announced its participation in two investor conferences in June 2024. The company will present at the Jefferies Global Healthcare Conference on June 5 at 8:30 a.m. ET and the Goldman Sachs Annual Global Healthcare Conference on June 10 at 3:20 p.m. ET. Both events will feature fireside chats with Enliven's management. The sessions will be webcast live and available on the company's investor relations website, with archives accessible for 30 days post-event.
Enliven Therapeutics announced positive results from its Phase 1 trial of ELVN-001 for chronic myeloid leukemia, showing a 44% major molecular response (MMR) rate by 12 weeks. The company has $321 million in cash, extending its runway to late 2026. A $90 million PIPE financing and board appointment of Lori Kunkel were highlighted. Enliven also advanced its ELVN-002 trial for HER2+ cancers, with the first site activated and patient dosing expected in Q2 2024. Financial results showed increased R&D and G&A expenses, leading to a net loss of $22.7 million for Q1 2024, compared to $14.7 million in Q1 2023.
FAQ
What is the current stock price of Enliven Therapeutics (ELVN)?
What is the market cap of Enliven Therapeutics (ELVN)?
What does Enliven Therapeutics, Inc. specialize in?
What are Enliven Therapeutics' main product candidates?
Where is Enliven Therapeutics located?
Who supports Enliven Therapeutics financially?
What is the focus of Enliven Therapeutics' research and development?
What recent event did Enliven Therapeutics host?
How can I access the recent webcast hosted by Enliven Therapeutics?
What makes Enliven Therapeutics' approach unique?
What is ELVN-001?
What type of company is Enliven Therapeutics?
